Learning to Align Molecules and Proteins: A Geometry-Aware Approach to Binding Affinity
By: Mohammadsaleh Refahi , Bahrad A. Sokhansanj , James R. Brown and more
Potential Business Impact:
Finds new medicines faster by predicting how they'll work.
Accurate prediction of drug-target binding affinity can accelerate drug discovery by prioritizing promising compounds before costly wet-lab screening. While deep learning has advanced this task, most models fuse ligand and protein representations via simple concatenation and lack explicit geometric regularization, resulting in poor generalization across chemical space and time. We introduce FIRM-DTI, a lightweight framework that conditions molecular embeddings on protein embeddings through a feature-wise linear modulation (FiLM) layer and enforces metric structure with a triplet loss. An RBF regression head operating on embedding distances yields smooth, interpretable affinity predictions. Despite its modest size, FIRM-DTI achieves state-of-the-art performance on the Therapeutics Data Commons DTI-DG benchmark, as demonstrated by an extensive ablation study and out-of-domain evaluation. Our results underscore the value of conditioning and metric learning for robust drug-target affinity prediction.
Similar Papers
Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery
Machine Learning (CS)
Finds new medicines faster by looking at how they fit.
Accurate and generalizable protein-ligand binding affinity prediction with geometric deep learning
Computational Engineering, Finance, and Science
Finds new medicines by predicting how they stick to bodies.
A Geometric Graph-Based Deep Learning Model for Drug-Target Affinity Prediction
Biomolecules
Finds best medicines for diseases faster.